(Q42221101)

English

Early impact of sequential introduction of 7-valent and 13-valent pneumococcal conjugate vaccine on IPD in Israeli children <5 years: an active prospective nationwide surveillance

scientific article published on 30 March 2014

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

Early impact of sequential introduction of 7-valent and 13-valent pneumococcal conjugate vaccine on IPD in Israeli children <5 years: an active prospective nationwide surveillance (English)

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

0 references

1 reference

based on heuristic

inferred from title

pneumococcal conjugate vaccine

1 reference

based on heuristic

inferred from title

Noga Givon-Lavi

3

object named as

Noga Givon-Lavi

0 references

8

object named as

Ron Dagan

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

author name string

Shalom Ben-Shimol

1

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

David Greenberg

2

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

Noga Givon-Lavi

3

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

Yechiel Schlesinger

4

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

Eli Somekh

5

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

Shraga Aviner

6

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

Dan Miron

7

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

language of work or name

0 references

publication date

30 March 2014

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

number of pages

8

1 reference

based on heuristic

inferred from page(s)

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

32

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

27

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

3452-3459

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

Rapid reduction in invasive pneumococcal disease after introduction of PCV7 into the National Immunization Plan in Israel

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.065

7 January 2021

Pediatric invasive pneumococcal disease in the United States in the era of pneumococcal conjugate vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.065

7 January 2021

Burden of invasive pneumococcal disease and serotype distribution among Streptococcus pneumoniae isolates in young children in Europe: impact of the 7-valent pneumococcal conjugate vaccine and considerations for future conjugate vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.065

7 January 2021

Serotype-specific changes in invasive pneumococcal disease after pneumococcal conjugate vaccine introduction: a pooled analysis of multiple surveillance sites

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.065

7 January 2021

Early trends for invasive pneumococcal infections in children after the introduction of the 13-valent pneumococcal conjugate vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.065

7 January 2021

Decrease of invasive pneumococcal infections in children among 8 children's hospitals in the United States after the introduction of the 7-valent pneumococcal conjugate vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.065

7 January 2021

Invasive pneumococcal disease caused by nonvaccine serotypes among alaska native children with high levels of 7-valent pneumococcal conjugate vaccine coverage

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.065

7 January 2021

Four years of universal pneumococcal conjugate infant vaccination in Germany: Impact on incidence of invasive pneumococcal disease and serotype distribution in children

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.065

7 January 2021

Serotype replacement in disease after pneumococcal vaccination

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.065

7 January 2021

Invasive Pneumococcal Disease a Decade after Pneumococcal Conjugate Vaccine Use in an American Indian Population at High Risk for Disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.065

7 January 2021

Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.065

7 January 2021

Decline in Invasive Pneumococcal Disease after the Introduction of Protein–Polysaccharide Conjugate Vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.065

7 January 2021

Impact of introduction of conjugate vaccines in the vaccination schedule on the incidence of pediatric invasive pneumococcal disease requiring hospitalization in Madrid 2007 to 2011.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.065

7 January 2021

The worldwide impact of the seven-valent pneumococcal conjugate vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.065

7 January 2021

Impact of the 7-valent pneumococcal conjugate vaccine on the incidence of childhood pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.065

7 January 2021

Impact of the seven-valent pneumococcal conjugate vaccination (PCV7) programme on childhood hospital admissions for bacterial pneumonia and empyema in England: national time-trends study, 1997-2008.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.065

7 January 2021

Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a time-series analysis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.065

7 January 2021

The impact of the heptavalent pneumococcal conjugate vaccine on the epidemiology of acute otitis media complicated by otorrhea

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.065

7 January 2021

Nasopharyngeal carriage of Streptococcus pneumoniae in Taiwan before and after the introduction of a conjugate vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.065

7 January 2021

Nasopharyngeal flora in children with acute otitis media before and after implementation of 7 valent pneumococcal conjugate vaccine in France

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.065

7 January 2021

Effects of routine infant vaccination with the 7-valent pneumococcal conjugate vaccine on nasopharyngeal colonization with streptococcus pneumoniae in children in Calgary, Canada.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.065

7 January 2021

Effectiveness of the new serotypes in the 13-valent pneumococcal conjugate vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.065

7 January 2021

Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.065

7 January 2021

Cost-effectiveness of 13-valent pneumococcal conjugate vaccine: Germany, Greece, and The Netherlands

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.065

7 January 2021

Mathematical modelling long-term effects of replacing Prevnar7 with Prevnar13 on invasive pneumococcal diseases in England and Wales

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.065

7 January 2021

Prevention of antibiotic-nonsusceptible Streptococcus pneumoniae with conjugate vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.065

7 January 2021

Hospitalized children with pneumonia in Uruguay: pre and post introduction of 7 and 13-valent pneumococcal conjugated vaccines into the National Immunization Program

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.065

7 January 2021

Incidence of hepatitis A in Israel following universal immunization of toddlers.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.065

7 January 2021

A decade (1989-1998) of pediatric invasive pneumococcal disease in 2 populations residing in 1 geographic location: implications for vaccine choice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.065

7 January 2021

Comparative immunogenicity and efficacy of 13-valent and 7-valent pneumococcal conjugate vaccines in reducing nasopharyngeal colonization: a randomized double-blind trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.065

7 January 2021

An epidemic of pneumococcal disease in an overcrowded, inadequately ventilated jail

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.065

7 January 2021

Emergence of Streptococcus pneumoniae serotypes 19A, 6C, and 22F and serogroup 15 in Cleveland, Ohio, in relation to introduction of the protein-conjugated pneumococcal vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.065

7 January 2021

Serotype specific invasive capacity and persistent reduction in invasive pneumococcal disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.065

7 January 2021

Invasive pneumococcal disease after routine pneumococcal conjugate vaccination in children, England and Wales

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.065

7 January 2021

Modeling the impact of the 13-valent pneumococcal conjugate vaccine serotype catch-up program using United States claims data

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.065

7 January 2021

Identifiers

10.1016/J.VACCINE.2014.03.065

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42221101&oldid=1936234463"